Chemical Structure (Pomalidomide 01)
Pomalidomide Capsule
Product Images NDC 51991-342
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Pomalidomide (NDC 51991-342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Breckenridge Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Pomalidomide 02)
Figure 2 (Pomalidomide 03)
This text appears to be a statistical data report. It includes information about subjects, treatments, proportions, and survival rates. The report mentions different treatments like POMILDDEX and HD-DEX, focusing on their effects on subjects. It also includes statistical figures such as percentages and medians. The section "Overal Survival (Morth)" may refer to the overall survival rates over a certain period.*
Principal Display Panel (1 mg Capsule Bottle Label)
This is a description of a medication containing Pomalidomide 1 mg in capsule form. The capsules should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). There is a warning about the potential for human birth defects. The medication guide is to be dispensed to each patient by the pharmacist. The product is distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited in India.*
Principal Display Panel (2 mg Capsule Bottle Label)
The text provides information about Pomalidomide capsules containing 2 mg each. It also includes storage instructions, dosage information, and a warning about potential birth defects. The product is to be dispensed with a Medication Guide to each patient. The capsules are distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited in India. The expiration date is listed as 08/2025.*
Principal Display Panel (3 mg Capsule Bottle Label)
The text provided is a description of a medication capsule containing Pomalidomide 3 mg. It also includes storage instructions, dosage information, a warning about potential birth defects, and details about distribution and manufacturing. This medication should be stored at 20°C to 25°C (68°F to 77°F), with permitted excursions to 15°C to 30°C (59°F to 86°F). Pharmacies are advised to dispense a Medication Guide to each patient. The medication is distributed by Breckenridge Pharmaceutical, Inc. and manufactured by Natco Pharma Limited in India.*
Principal Display Panel (4 mg Capsule Bottle Label)
This is a medication label for Pomalidomide capsules, with each capsule containing 4 mg of the active ingredient. The storage conditions recommend keeping it between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The label includes dosage instructions, and there is a warning about the potential for human birth defects with this medication. It also instructs pharmacists to dispense the enclosed Medication Guide to each patient. The product is distributed by Breckenridge Pharmaceutical, Inc., and manufactured by Natco Pharma Limited in India. The label also includes an expiration date of 08/2025 and important identification numbers for the product.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
